Volume 13, Number 5—May 2007
Dispatch
Antimicrobial Drugs and Community–acquired Clostridium difficile–associated Disease, UK
J. A. Chris Delaney*, Sandra Dial*, Alan Barkun*, and Samy Suissa*
Table 2
Most recent prescription for any antimicrobial drug and effect of proximity on risk of acquiring Clostridium difficile–associated disease, UK, 1993–2004*
| Exposure to antimicrobial drug | Case-patients, n = 1,233 (%) | Control-patients, n = 12,330 | Crude OR | Adjusted OR (95% CI)† |
|---|---|---|---|---|
| None (reference) | 379 (30) | 6,449 (52) | 1.0 | 1.0 (reference) |
| Most recent prescription‡ | ||||
| 1–90 d (current) | 456 (37) | 1,649 (13) | 5.0 | 3.7 (3.1–4.4) |
| 91–180 d | 128 (10%) | 1067 (9) | 2.2 | 1.8 (1.4–2.3) |
| 181–365 d | 131 (11) | 1,498 (12) | 1.6 | 1.3 (1.0–1.6) |
| 1–2 y | 139 (11) | 1,674 (13) | 1.5 | 1.3 (1.0–1.6) |
| Most recent fluoroquinolone prescription† | ||||
| 1 – 90 d (current) | 70 (5.7) | 84 (0.7) | 10.9 | 6.2 (4.4–8.8) |
| 91–180 d | 12 (1.0) | 70 (0.6) | 1.7 | 1.2 (0.6–2.3) |
| 181–365 d | 27 (2.2) | 114 (0.9) | 2.4 | 1.7 (1.1–2.7) |
| 1–2 y | 36 (2.9) | 198 (1.6) | 1.9 | 1.3 (0.9– 2.0) |
*OR, odds ratio; CI, confidence interval.
†Adjusted for inflammatory bowel disease, diverticular disease, peptic ulcer disease and gastroesophageal reflux disease,
Helicobacter pylori–associated disease, pernicious anemia, cancer including solid tumor and hematologic malignancies, diabetes
mellitus, chronic obstructive pulmonary disease, cirrhosis, nonsteroidal anti-inflammatory agents, aspirin, H2 blockers, proton pump
inhibitors, and antimicrobial use in the past 2 years.
‡2 y before the index date.
Page created: June 23, 2010
Page updated: June 23, 2010
Page reviewed: June 23, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.